Aktueller stand der bisphosphonattherapie in der hämato-onkologie

Translated title of the contribution: Current status of bisphosphonate therapy in hemato-oncology

A. Grothey, W. Dempke

Research output: Contribution to journalReview articlepeer-review


The introduction of bisphosphonates in oncology has substantially broadened the therapeutic spectrum in the treatment of osseous manifestations of malignant diseases. In particular, in patients with breast cancer and multiple myeloma bisphosphonates are able to prevent the occurrence of skeletal complications in certain clinical situations. However, several questions remain unanswered, notably regarding the value of bisphosphonates for subgroups of patients and the optimal duration of therapy. In other tumor types the data on bisphosphonates is much less clear which precludes the formulation of guidelines for their clinical use until reliable information based on prospective clinical trials becomes available. The increased activity of novel bisphosphonates such as ibandronate and zoledronate may in the future open the field for innovative applications of these drugs in oncology.

Translated title of the contributionCurrent status of bisphosphonate therapy in hemato-oncology
Original languageGerman
Pages (from-to)291-299
Number of pages9
JournalInternistische Praxis
Issue number2
StatePublished - Jan 1 2002


  • Bisphosphonates
  • Breast cancer
  • Multiple myeloma

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Current status of bisphosphonate therapy in hemato-oncology'. Together they form a unique fingerprint.

Cite this